|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs121913227
|
|
|
0.800 |
GeneticVariation |
BEFREE |
V600R-mutant melanoma accounts for a significant number of cases even in single-institution practices.
|
31305324 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs121913377
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs763538721
|
|
|
0.040 |
GeneticVariation |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs1320553543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs45430
|
|
|
0.820 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previously reported as a novel melanoma susceptibility locus in genome-wide association studies.
|
31660681 |
2019 |
|
rs1057519695
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The activating NRAS p.Q61R variant is a known "hotspot" variant, frequently identified in several types of human cancer, especially melanoma.
|
30542204 |
2019 |
|
rs1057519695
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
rs1057519834
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The activating NRAS p.Q61R variant is a known "hotspot" variant, frequently identified in several types of human cancer, especially melanoma.
|
30542204 |
2019 |
|
rs1057519834
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
By using genetic material collected noninvasively and to further validate the PLA, somatic hotspot mutations in genes known to be drivers of early melanoma development (BRAF other than V600E, NRAS, and the TERT promoter) can also be identified.
|
30500343 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The most prevalent BRAF mutation, V600E, occurs frequently in melanoma and other cancers.
|
31152574 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We established vemurafenib-resistant (VR) cells from three BRAF (V600E)-mutated melanoma lines (C32, HMY-1, and SK-MEL-28) and evaluated the mechanism of acquired resistance of VR cells by water-soluble tetrazolium salts assay, western blot, real-time quantitative PCR, and immunofluorescent microscopy.
|
30920401 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we present a case of pulmonary melanocytic nevus, involving a BRAF gene mutation (V600E), and we discuss the potential significance of this condition as a precursor to pulmonary malignant melanoma.
|
31556191 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This study reviews the management of BRAF-V600E mutant melanoma with ependymal involvement.
|
30972290 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The data reveal a very close link between the two methods, supporting the use of the V600E as a primary screen for BRAF mutations in malignant melanoma.
|
30870099 |
2019 |